Symbiotec Pharmalab IPO Day 2: Subscription Status, Timeline & Key Issue Details

Symbiotec Pharmalab's ₹1,757.0 crore initial public offering (IPO)entered its second day of public subscription today, August 25, 2026, with a price band of ₹938 to ₹988 per share. As of 10:18 A.M on the second day of bidding, the issue had been subscribed 1.00 times.

The IPO will remain open for subscription until 27 August 2026. The basis of allotment is expected to be finalised on 28 August 2026, while the shares are tentatively scheduled to be listed on the NSE and BSE on 1 September 2026.

Symbiotec Pharmalab IPO - Issue Details

• Issue Type: Book Built Issue (Fresh Issue + OFS)
• Total Issue Size: Up to ₹1,757.00 crore
• Fresh Issue: Up to ₹150.00 crore
• Offer for Sale (OFS): Up to ₹1,607.00 crore
• Face Value: ₹2 per equity share
• Price Band: ₹938 to ₹988 per share
• Lot Size: 15 shares
• Minimum Investment Amount (Retail Investor): ₹14,820 (15 shares at the upper price)
• Listing: BSE, NSE
• Book Running Lead Managers: JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited, Nomura Financial Advisory and Securities (India) Private Limited
• Registrar: MUFG Intime India Private Limited

Symbiotec Pharmalab IPO Timeline (Tentative)

The expected IPO schedule is as follows:

Note: The allotment and listing dates are tentative and may be revised.

Explore other Upcoming IPOs on BSE and NSE.

Symbiotec Pharmalab IPO Day 2 Subscription Status

[August 25, 2026, 10:18 A.M.]

Utilisation of IPO Proceeds

The company intends to utilise the net proceeds from the fresh issue towards:

• Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company
• General corporate purposes.

About Symbiotec Pharmalab Limited

Incorporated in 2002, Symbiotec Pharmalab Limited is a research-driven pharmaceutical and biotechnology company focused on the development and manufacturing of active pharmaceutical ingredients (APIs), complex injectables, and biotechnology-based products. It is a global leader in corticosteroid and steroidal hormone APIs by production volume and markets a portfolio of more than 60 APIs across regulated pharmaceutical markets.

The company operates a vertically integrated manufacturing ecosystem in Madhya Pradesh, comprising API, fermentation, and injectable production facilities. In addition to its own product portfolio, Symbiotec offers contract development and manufacturing (CDMO) services to global pharmaceutical and nutraceutical companies, backed by multiple international regulatory certifications.

Key Financial Highlights 

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.   

To read the RA disclaimer, please click here